EXTON, Pa., Nov. 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced it will present at the Lazard Capital Markets Annual Life Sciences Conference at 3:30 P.M. ET on Tuesday, November 28, 2006. The conference is being held at The Palace Hotel, in New York City.
ViroPharma also announced that it will be presenting at the Piper Jaffray Healthcare Conference at 8:30 A.M. ET on Wednesday, November 29, 2006. The conference is being held at The Pierre Hotel, also in New York City.
ViroPharma’s presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conference.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company’s website at http://www.viropharma.com.
ViroPharma Incorporated
CONTACT: William C. Roberts, Director, Corporate Communications,+1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications,+1-610-321-6290, both of ViroPharma Incorporated
Web site: http://www.viropharma.com/
